ATE422215T1 - Strategie zur unterdruckung der expression eines endogenen genes durch verwendung von verbindungen,die an die nicht-kodierenden regionen des zu hemmenden genes binden können - Google Patents

Strategie zur unterdruckung der expression eines endogenen genes durch verwendung von verbindungen,die an die nicht-kodierenden regionen des zu hemmenden genes binden können

Info

Publication number
ATE422215T1
ATE422215T1 AT96931887T AT96931887T ATE422215T1 AT E422215 T1 ATE422215 T1 AT E422215T1 AT 96931887 T AT96931887 T AT 96931887T AT 96931887 T AT96931887 T AT 96931887T AT E422215 T1 ATE422215 T1 AT E422215T1
Authority
AT
Austria
Prior art keywords
gene
strategy
coding regions
expression
bind
Prior art date
Application number
AT96931887T
Other languages
English (en)
Inventor
Gwenyth Farrar
Peter Humphries
Paul Kenna
Original Assignee
Optigen Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optigen Patents Ltd filed Critical Optigen Patents Ltd
Application granted granted Critical
Publication of ATE422215T1 publication Critical patent/ATE422215T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96931887T 1995-09-21 1996-09-23 Strategie zur unterdruckung der expression eines endogenen genes durch verwendung von verbindungen,die an die nicht-kodierenden regionen des zu hemmenden genes binden können ATE422215T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9519299.3A GB9519299D0 (en) 1995-09-21 1995-09-21 Genetic strategy

Publications (1)

Publication Number Publication Date
ATE422215T1 true ATE422215T1 (de) 2009-02-15

Family

ID=10781063

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96931887T ATE422215T1 (de) 1995-09-21 1996-09-23 Strategie zur unterdruckung der expression eines endogenen genes durch verwendung von verbindungen,die an die nicht-kodierenden regionen des zu hemmenden genes binden können

Country Status (10)

Country Link
US (2) US6713457B2 (de)
EP (1) EP0851918B1 (de)
AT (1) ATE422215T1 (de)
AU (1) AU7089696A (de)
CA (1) CA2232738C (de)
DE (1) DE69637831D1 (de)
ES (1) ES2321461T3 (de)
GB (1) GB9519299D0 (de)
NZ (1) NZ318818A (de)
WO (1) WO1997011169A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519299D0 (en) 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy
GB9604449D0 (en) * 1996-03-01 1996-05-01 Farrar Gwyneth J Genetic strategy ii
GB9606961D0 (en) 1996-04-02 1996-06-05 Farrar Gwyneth J Genetic strategy III
US20040234999A1 (en) * 1996-04-02 2004-11-25 Farrar Gwenyth Jane Genetic suppression and replacement
US8551970B2 (en) * 1996-04-02 2013-10-08 Optigen Patents Limited Genetic suppression and replacement
WO1998048027A2 (en) * 1997-04-21 1998-10-29 University Of Florida Materials and methods for treatment of retinal diseases
CA2287508A1 (en) 1997-04-21 1998-10-29 The University Of Florida Materials and methods for ribozyme treatment of retinal diseases
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
AU781598B2 (en) * 1999-04-21 2005-06-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibiting the function of polynucleotide sequences
WO2000066780A2 (en) 1999-04-30 2000-11-09 University Of Florida Adeno-associated virus-delivered ribozyme compositions and methods of use
GB0403600D0 (en) * 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
EP1764107A1 (de) * 2005-09-14 2007-03-21 Gunther Hartmann Zusammensetzungen enthaltend immunstimulierende RNA-Oligonukleotide und Methoden zu deren Herstellung
US8557787B2 (en) 2011-05-13 2013-10-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JPH0376580A (ja) 1989-08-17 1991-04-02 Japan Tobacco Inc 大腸菌発現ベクターとそれを利用した抗ウイルス性タンパク質の製造方法
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5223391A (en) * 1990-02-21 1993-06-29 President And Fellows Of Harvard College Inhibitors of herpes simplex virus replication
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
NO312681B1 (no) 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
CA2094938A1 (en) 1991-01-04 1992-07-05 Grant R. Sutherland Dna sequences related to isolated fragile x syndrome
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
CA2111472A1 (en) * 1991-06-14 1992-12-23 Brett P. Monia Antisense oligonucleotide inhibition of the ras gene
AU3274793A (en) 1991-12-12 1993-07-19 Hybritech Incorporated Enzymatic inverse polymerase chain reaction library mutagenesis
IL101600A (en) * 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US6107062A (en) 1992-07-30 2000-08-22 Inpax, Inc. Antisense viruses and antisense-ribozyme viruses
WO1994011494A1 (en) * 1992-11-09 1994-05-26 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
CA2159195A1 (en) * 1993-03-26 1994-10-13 Darwin J. Prockop Use of a col 1a1 mini-gene construct to inhibit collagen synthesis
CN1123038A (zh) 1993-05-11 1996-05-22 北卡罗来纳大学查珀尔希尔分校 阻止异常剪接的反义寡核苷酸及其使用方法
US6025127A (en) * 1994-01-14 2000-02-15 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection in histologic tissue
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis
WO1995034573A1 (en) 1994-06-03 1995-12-21 Brigham And Women's Hospital Identification of polycystic kidney disease gene, diagnostics and treatment
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US6482803B1 (en) * 1995-09-01 2002-11-19 Board Of Regents, The University Of Texas System Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
GB9519299D0 (en) 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy
WO1997044348A1 (en) * 1996-05-17 1997-11-27 Thomas Jefferson University Ribozyme-mediated gene replacement
US5814500A (en) 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use

Also Published As

Publication number Publication date
GB9519299D0 (en) 1995-11-22
AU7089696A (en) 1997-04-09
WO1997011169A2 (en) 1997-03-27
EP0851918A2 (de) 1998-07-08
US6713457B2 (en) 2004-03-30
US20030096767A1 (en) 2003-05-22
CA2232738A1 (en) 1997-03-27
ES2321461T3 (es) 2009-06-05
EP0851918B1 (de) 2009-02-04
US20040254138A1 (en) 2004-12-16
NZ318818A (en) 2000-06-23
WO1997011169A3 (en) 1997-06-12
DE69637831D1 (de) 2009-03-19
CA2232738C (en) 2010-11-23

Similar Documents

Publication Publication Date Title
ATE422215T1 (de) Strategie zur unterdruckung der expression eines endogenen genes durch verwendung von verbindungen,die an die nicht-kodierenden regionen des zu hemmenden genes binden können
EP1092771A3 (de) Tetracyclin-regulierte Transcriptionsmodulatoren
ATE513911T1 (de) Verfahren und zusammensetzungen für rna- interferenz
ATE206465T1 (de) Verfahren zur unterdrückung der hemmung von enzym-vermittelten reaktionen durch ionische detergentien
AU2022295A (en) Nucleic acid amplification with DNA-dependant RNA polymerase activity of RNA replicases
DE60030988D1 (de) Verfahren zur Herstellung Von L-Aminosäuren durch Erhöhung des zellulären NADPH
DK0966465T3 (da) Inhibitorer af IMPDH-enzymer
DE69638061D1 (de) Onkogenische mutanten des genes tsg101
GB2325302B (en) Cross-species chromosome painting
ATE166066T1 (de) Schutz von nukleinsäuren und verfahren zur analyse
DE59909391D1 (de) Verfahren zur Herstellung von Pantothensäure durch Verstärkung von für Ketopantoat-Reduktase kodierende Nukleotidsequenzen
AU7517496A (en) Methods for preparing solid supports for hybridization and reducing non-specific background
DE69810351D1 (de) Verfahren zur begrenzung des wachstums von mikroorganismen durch verwendung metallhaltiger verbindungen
ATE250077T1 (de) Steroid sulfataseinhibitoren, verfahren zu ihrer herstellung und verwendung
ATE399749T1 (de) Verfahren zur hydrierung von methylolalkanalen
HUP9802681A1 (hu) Onkogénnel vagy vírussal szabályozott expressziós rendszerek
Rovera et al. Ghost monolayers in the study of the modulation of transcription in cultures of CV1 fibroblasts
DE69941451D1 (de) Verfahren zur unterdrückung der genexpression in pflanzen
GB2397825A (en) Method of producing human beta cell lines
HUP0100126A2 (hu) Előaktivált kiméra transzkripciós faktorok
SG125896A1 (en) A method for regulating gene expression
O’Neill et al. The role of ncRNA in centromeres: a lesson from marsupials
DE60130465D1 (de) Mutierte muskelspezifische enhancer
DE50105621D1 (de) 1h-pyrazol-derivate, verfahren zu ihrer herstellung und deren verwendung zur hemmung und steuerung der nitrifikation
DE69924718D1 (de) Gen 62 des attenuierten windpocken-virusstammes oka und verfahren zur identifikation eines attenuierten, lebenden windpockenvirusstammes unter verwendung dieses genes.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties